Jürgen Polifka, Director of Global Market Access at Advanz Pharma, provides a Special Report on the company's approach to securing rapid access for essential me 17 December 2021
A Special Report on the top five trends redefining the way healthcare stakeholders look at long-term healthcare access sustainability in the region from Roshel 28 April 2021
Reducing patient healthcare costs is imperative, write Matthew Majewski and Andrew Parece, vice presidents of Charles River Associates, in a Special Report. 21 October 2020
In a Special Report, Patrick Laroche, Janssen EMEA Haematology Therapy Area Lead, looks at how haematology is leading the way in oncology innovation, how CAR-T 28 January 2020
For our latest Special Report, Adriaan Fruijtier from CATS Consultants, gives an account of major talking points at one of the year’s major events in the calend 22 July 2019
Joseph Saba, chief executive of Axios International, a healthcare organization specialized in access in developing countries, writes an exclusive Special Report 9 January 2019
In a special report piece, Ed Corbett, principal at specialist pharmaceutical strategy consultants, Novasecta, considers an issue of paramount importance to the 3 October 2018
In our latest Special Report.Ali Hansford.head of social policy at the Association of the British Pharmaceutical Industry (ABPI).discusses the UK government's p 18 May 2018
Our latest Special Report is a review of key factors impeding progress of US biosimilar adoption written by Helen Ji.an associate at Schiff Hardin LLP.Rekha Han 4 April 2018
The final Special Report of 2017 comes from Scott Pescatore, the Europe region general manager for rare diseases at Novartis Oncology, and is an overview of how 19 December 2017
Science writer David Levine provides the latest quarterly Special Report piece, looking at the drug prices in one therapy area that are getting on people's nerv 29 September 2017
In a quarterly special report piece Andrew Williams, patent law expert, partner at Chicago-based IP law firm McDonnell Boehnen Hulbert & Berghoff and chair of i 25 July 2017
Non-alcoholic steatohepatitis (NASH).the most severe form of non-alcoholic fatty liver disease (NAFLD).has been generating grave concern throughout the medical 30 March 2017
Our quarterly Special Report from experts at QuintilesIMS provides practical scientific and practical insights on Post Authorization Safety Studies based on the 29 December 2016
In our quarterly special report, Dr Michelle Maxwell reports on the fast-moving world of biosimilars and explores the opportunities that are opening up for deve 8 September 2016
Personalized medicine was born more than 20 years ago through the ambitious plan to sequence the first reference human genome.This was accomplished in 2003 at t 9 June 2016
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.